Central Nervous System

PV QA 2 - Poster Viewing Q&A 2

MO_15_2827 - Endocrine Remission after Pituitary Stereotactic Radiosurgery:Differences in Rates of Response for Matched Cohorts of Cushing's Disease and Acromegaly Patients

Monday, October 22
10:45 AM - 12:15 PM
Location: Innovation Hub, Exhibit Hall 3

Endocrine Remission after Pituitary Stereotactic Radiosurgery:Differences in Rates of Response for Matched Cohorts of Cushing’s Disease and Acromegaly Patients
D. M. Trifiletti1, Z. Xu2, S. W. Dutta3, A. Quinones-Hinojosa4, J. L. Peterson1, M. L. Vance5, and J. P. Sheehan6; 1Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL, 2University of Virginia Health System, Charlottesville, VA, 3Department of Radiation Oncology, University of Virginia, Charlottesville, VA, 4Department of Neurosurgery, Mayo Clinic, Jacksonville, FL, 5Department of Medicine, University of Virginia, Charlottesville, VA, 6Department of Neurosurgery, University of Virginia, Charlottesville, VA

Purpose/Objective(s): To compare and describe the time to endocrine remission and new hypopituitarism among patients with growth hormone (GH) and adrenocorticotropic hormone (ACTH) secreting pituitary adenomas after radiosurgery after controlling for several known prognostic factors.

Materials/Methods: An IRB approved, institutional retrospective analysis of patients with GH- and ACTH-secreting pituitary adenomas was performed, with matching based on patient gender, age at radiosurgery, time interval between the last resection and radiosurgery, use of previous radiotherapy, whole sella treatment, suprasellar extension, cavernous sinus invasion, and margin dose. Endocrine remission was defined, off of suppressive medications, as a normal serum IGF-1 (GH-secreting) or a normal 24-hour urine free-cortisol (ACTH-secreting). Endocrine remission and the incidence of new hypopituitarism after single fraction radiosurgery were described and compared between groups.

Results: Two-hundred and forty-two (242) patients were evaluated, 121 with GH-secreting tumors and 121 with ACTH-secreting tumors. 75% of patients had cavernous sinus invasion and 10% had suprasellar extension at the time of radiosurgery. The median radiosurgical marginal dose was 25 Gy to the 50% isodose line between each group. After multivariable adjustment, factors associated with increased time to endocrine remission included patient age (HR 1.016, p = 0.023), cavernous sinus invasion (HR 1.793, p = 0.004), and patients with acromegaly (HR 2.912, p < 0.001). The incidence of a new hypopituitarism developing after SRS was 29% and did not appreciably differ by adenoma subtype (p = 0.180).

Conclusion: After radiosurgery, patients with ACTH-secreting tumors achieve endocrine remission sooner than those with GH-secreting tumors. These results provide insight into the relative tumor biology and post-radiosurgical disease course that will serve to further improve clinical outcomes and patient management in the future.

Author Disclosure: D.M. Trifiletti: Member; ARRO. Z. Xu: None. S.W. Dutta: None. A. Quinones-Hinojosa: None. J.L. Peterson: None. M. Vance: None. J.P. Sheehan: secretary; N2QOD.

Send Email for Sunil Dutta


Assets

MO_15_2827 - Endocrine Remission after Pituitary Stereotactic Radiosurgery:Differences in Rates of Response for Matched Cohorts of Cushing's Disease and Acromegaly Patients



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Endocrine Remission after Pituitary Stereotactic Radiosurgery:Differences in Rates of Response for Matched Cohorts of Cushing's Disease and Acromegaly Patients